Ageing
9 videos · updated daily
23:17 Alex Zhavoronkov on AI Drug Discovery at the Nature Conference
Insilico Medicine founder and CEO Alex Zhavoronkov describes the company's AI-driven drug discovery model, the advance of rentosertib into Phase III and a Phase IIa study using proteomic aging clocks, at a Nature Conference in Paris.
2:48:26 Gerotherapeutic Regulatory Constructs: Afternoon Session
The Reagan-Udall Foundation for the FDA, with ARPA-H and the XPRIZE Foundation, holds a public meeting on regulatory pathways for gerotherapeutic drugs, biologics and devices, including industry views on what sponsors need from FDA.
1:26 STAREE: Atorvastatin and Cardiovascular Events in Older Adults
NEJM summarises the STAREE trial, in which atorvastatin in older adults without cardiovascular disease led to a lower risk of major cardiovascular events than placebo at a median of 5.9 years but did not lengthen disability-free survival.
9:33 Rentosertib: From AI-Discovered Target to Phase 3
Insilico Medicine traces rentosertib, a TNIK inhibitor designed with AI for fibrosis, from target discovery through Phase 2a to Phase 3, where it was in September 2026, and an analysis applying six proteomic aging clocks to Phase 2a trial data.
10:06 Proteomic Aging Clocks in a Phase 2a Trial
Fedor Galkin, Director of Longevity AI Research at Insilico Medicine, walks through the company's Nature Biotechnology paper applying proteomic aging clocks to data from a Phase 2a clinical trial.
2:18:22 Gerotherapeutic Regulatory Constructs: Morning Session
In the morning session of a Reagan-Udall Foundation for the FDA public meeting with ARPA-H and XPRIZE, speakers cover what ageing trials have taught about endpoints, populations and feasibility, and multi-domain endpoints for gerotherapeutics.
2:27 Can an AI Medication Dispenser Help Older Adults With Memory Loss?
UC Davis Health researchers describe a clinical trial, funded by a National Institute on Aging SBIR grant, of whether the HiDO AI-assisted medication dispenser improves adherence in people with mild cognitive impairment to moderate dementia.
58:38 Navigating Clinical Trials for Alzheimer’s Disease
Dr. Jeffrey L. Cummings, a researcher in dementia drug development, explains the types of Alzheimer's research studies, how participants qualify and the phases of trials, for BrightFocus Foundation.
23:02 What Clinical Trial Patients Need: A 1,000-Patient Study
Kayentis presents results of a study of more than 1,000 patients, run with patient associations in the US and Europe, on why patients do or do not take part in clinical studies and how they view digital and decentralised trials.